# BridgeBio Oncology Therapeutics, Inc. > Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero. ## Record | Field | Value | | --- | --- | | Representation | alpha-profile-markdown-v4 | | Protocol | Alpha Governance Facts Protocol 0.1 | | Schema | alpha.governance.entity.public.v1 | | Record version | public-1 | | Governance record representation | alpha-governance-record-v2 | | Canonical entity | alpha:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f | | Entity type | Company | | Canonical URL | https://registry.alpha.ac/companies/bridgebio-oncology-therapeutics-inc | | Publication | PUBLISHED | | Verification | source_reported | | Verification schema | alpha-verification-states-v1 | | Ownership | unclaimed | | Published claims | 20 | | Claims under review | 1 | | Evidence records | 5 | | Conflicts | 0 | | Conflicts in internal review | 0 | | Observed | 2026-10-04T04:46:28.768589+00:00 | | Last reviewed | 2026-10-04T04:46:28.768589+00:00 | ## Identity - Legal name: BridgeBio Oncology Therapeutics, Inc. - Display name: BridgeBio Oncology Therapeutics, Inc. ## Role modules - NOT_ASSERTED ## Attention - NO_RECORDS_FOUND ## Committee data - NO_RECORDS_FOUND ## Leadership - Jake Bauer: Chairman of the Board. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:leadership_role:5. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:59acdd75dbb4a409feb947c32718a509592d6cb8b175292f5e9c7e1ce1811b3a. - Bihua Chen, M.B.A.: Director. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:leadership_role:6. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:59acdd75dbb4a409feb947c32718a509592d6cb8b175292f5e9c7e1ce1811b3a. - Frank P. McCormick, Ph.D., F.R.S., D.Sc.: Director. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:leadership_role:7. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:59acdd75dbb4a409feb947c32718a509592d6cb8b175292f5e9c7e1ce1811b3a. - Michelle Doig: Director. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:leadership_role:8. Valid from: 2021-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:4fb2caaa7b87f699564646847e39507307d10c4510786336f3cacd28be8b7dc3. - Neil Kumar: Director. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:leadership_role:9. Valid from: 2016-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:4fb2caaa7b87f699564646847e39507307d10c4510786336f3cacd28be8b7dc3. - Neil Kumar, Ph.D.: Executive Chairman of the Board. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:leadership_role:10. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:59acdd75dbb4a409feb947c32718a509592d6cb8b175292f5e9c7e1ce1811b3a. - Pedro J. Beltran, Ph.D.: Chief Executive Officer and Director. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:leadership_role:11. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:59acdd75dbb4a409feb947c32718a509592d6cb8b175292f5e9c7e1ce1811b3a. - Peter Lebowitz: Director. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:leadership_role:12. Valid from: 2024-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:4fb2caaa7b87f699564646847e39507307d10c4510786336f3cacd28be8b7dc3. - Peter Lebowitz, M.D., Ph.D.: Director. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:leadership_role:13. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:59acdd75dbb4a409feb947c32718a509592d6cb8b175292f5e9c7e1ce1811b3a. - Praveen Tipirneni, M.D., M.B.A.: Director. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:leadership_role:14. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:59acdd75dbb4a409feb947c32718a509592d6cb8b175292f5e9c7e1ce1811b3a. - Raymond Kelleher: Director. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:leadership_role:15. Valid from: 2024-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:4fb2caaa7b87f699564646847e39507307d10c4510786336f3cacd28be8b7dc3. - Raymond Kelleher, M.D., Ph.D.: Director. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:leadership_role:16. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:59acdd75dbb4a409feb947c32718a509592d6cb8b175292f5e9c7e1ce1811b3a. - Eli Wallace, Ph.D.: Chief Executive Officer and President. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:leadership_role:17. Valid from: 2026-04-28. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:8b2303f36f6ec815a7666e8fbf6d2fa62a3ea6eec91c90ebbafc8c675b1d6834. - Idan Elmelech: Chief Operating Officer. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:leadership_role:18. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:59acdd75dbb4a409feb947c32718a509592d6cb8b175292f5e9c7e1ce1811b3a. - Pedro J. Beltran, Ph.D.: Chief Executive Officer. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:leadership_role:19. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:59acdd75dbb4a409feb947c32718a509592d6cb8b175292f5e9c7e1ce1811b3a. - Uneek Mehra: Chief Financial Officer. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:leadership_role:20. Valid from: 2026-04-28. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:623cc5b73fa680065bca4d0583ebe97802a3965a3751f6a2d519839572b90204. - Yong Ben, M.D., M.B.A.: Chief Medical and Development Officer. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:leadership_role:21. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:59acdd75dbb4a409feb947c32718a509592d6cb8b175292f5e9c7e1ce1811b3a. ## Roles - PUBLISHED ## Governance - NOT_ASSERTED ## Board committees - PUBLISHED ## Financials - NOT_ASSERTED ## Workforce - NOT_ASSERTED ## Market and index context - PUBLISHED ## Legal Name - BridgeBio Oncology Therapeutics, Inc.. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:legal_name:1. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:87582eedadb599856a8197a9c2de0a573ea2932544dd0c541e1efedcdfa8c23c. ## Entity Status - Public listing published. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:entity_status:3. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:87582eedadb599856a8197a9c2de0a573ea2932544dd0c541e1efedcdfa8c23c. ## Published Fact - US. Claim: alpha:claim:company:b61e4e0a-2ea1-468b-a1bb-2065eda1737f:published_fact:4. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:87582eedadb599856a8197a9c2de0a573ea2932544dd0c541e1efedcdfa8c23c. ## Coverage states | Field | Value | | --- | --- | | Identity | PUBLISHED | | Business | PUBLISHED | | Leadership | PUBLISHED | | Board and committees | PUBLISHED | | Governance | NOT_ASSERTED | | Financials | NOT_ASSERTED | | Workforce | NOT_ASSERTED | | Ownership | NOT_ASSERTED | | Ratings | NOT_PUBLISHED | | Market and index context | PUBLISHED | ## Public sources - alpha:projection-evidence:87582eedadb599856a8197a9c2de0a573ea2932544dd0c541e1efedcdfa8c23c: [Alpha canonical company public projection](https://www.alpha.ac/api/public/companies/bridgebio-oncology-therapeutics-inc). - alpha:projection-evidence:document:59acdd75dbb4a409feb947c32718a509592d6cb8b175292f5e9c7e1ce1811b3a: [SEC DEF 14A 0001193125-26-186944](https://www.sec.gov/Archives/edgar/data/1869105/000119312526186944/d133143ddef14a.htm). - alpha:projection-evidence:document:4fb2caaa7b87f699564646847e39507307d10c4510786336f3cacd28be8b7dc3: [DEF 14A d133143ddef14a.htm](https://www.sec.gov/Archives/edgar/data/1869105/000119312526186944/d133143ddef14a.htm). - alpha:projection-evidence:document:8b2303f36f6ec815a7666e8fbf6d2fa62a3ea6eec91c90ebbafc8c675b1d6834: [BBOT DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1869105/000119312526186944/d133143ddef14a.htm). - alpha:projection-evidence:document:623cc5b73fa680065bca4d0583ebe97802a3965a3751f6a2d519839572b90204: [BBOT DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1869105/000119312526186944/d133143ddef14a.htm). ## Rights | Field | Value | | --- | --- | | public_retrieval | allowed | | agent_retrieval | allowed | | redistribution | not_granted | | model_training | not_granted | | commercial_use | not_specified | | relationship_pathfinding | not_granted | | direct_contact | not_granted | ## Limitations - Absence of a leadership role, committee, or disclosure is not evidence that it does not exist. - Only explicitly published canonical company identity and current confirmed public roles are included. - Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist. - Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights. - This Company Profile is an identity and evidence record, not an Alpha rating. ## Alternate representations - [Canonical profile](https://registry.alpha.ac/companies/bridgebio-oncology-therapeutics-inc) - [Public Markdown](https://registry.alpha.ac/companies/bridgebio-oncology-therapeutics-inc.md) - [Public JSON](https://registry.alpha.ac/api/public/companies/bridgebio-oncology-therapeutics-inc?format=record) - [JSON-LD](https://registry.alpha.ac/api/public/companies/bridgebio-oncology-therapeutics-inc?format=jsonld) - MCP resource: `alpha://companies/bridgebio-oncology-therapeutics-inc` at https://mcp.alpha.ac/mcp ## Connected governance records Structured intelligence is not currently available. Existing published profile evidence remains accessible.